Cargando…
601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours
Autores principales: | Gelderblom, H., Gietema, J.A., Desar, I.M.E., Ajmone, N.M., Jalving, M., Kroep, J.R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S.F., Damstrup, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506497/ http://dx.doi.org/10.1016/j.annonc.2020.08.715 |
Ejemplares similares
-
EHMTI-0123. New-onset headaches heralding demyelination
por: Vinjam, M, et al.
Publicado: (2014) -
DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
por: Thibault, Benoît, et al.
Publicado: (2018) -
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021) -
OA01.23. Impact of climate change on medicinal plants - A review
por: Harish, B. S., et al.
Publicado: (2012) -
PA01.23. Ayurvedic management of psoriasis: a comparative clinical study
por: Nikam, Dattatrya, et al.
Publicado: (2012)